BioCentury | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
BioCentury | Mar 25, 2019
Distillery Therapeutics

AbbVie's oral macrolide ABBV-4083 for lymphatic filariasis and onchocerciasis

DISEASE CATEGORY: Infectious disease INDICATION: Infectious Cell culture, mouse and gerbil studies identified an oral macrolide antibiotic that could help treat lymphatic filariasis and onchocerciasis, which are caused by Brugia malayi , Litomosoides sigmodontis , Onchocerca ochengi...
BioCentury | May 15, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
BioCentury | May 3, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies suggest a biotinoyl-deoxyadenosine-based inhibitor of M. tuberculosis BirA could help treat tuberculosis (TB) and reduce drug resistance. In M. tuberculosis cultures, a previously reported biotinylated analog of deoxyadenosine...
BioCentury | May 11, 2017
Strategy

Feeding the Young

Increasing funding for innovative young researchers is making its way up NIH ’s to-do list. But to win over a skeptical community, the agency will likely need to redraw some boundaries and dig a bit...
BioCentury | Sep 22, 2016
Translation in Brief

Hi-fi hybridomas

A team from ETH Zurich has developed a method for producing high-fidelity hybridomas by using CRISPR-based gene editing, and believes the system can address the unreliability of research antibodies that has fed into the "reproducibility...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Janus kinase (JAK); JAK-1; JAK-3

Autoimmune disease INDICATION: Ankylosing spondylitis Mouse studies suggest JAK inhibitors could help treat spondyloarthritis. In a mouse model of spondyloarthritis, the oral JAK-1 / JAK-3 inhibitor Xeljanz tofacitinib citrate decreased inflammation of the synovio-entheseal complex...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

...frequently. These included BRAF ; neuroblastoma Ras viral (v-Ras) oncogene (NRAS) ; K-Ras (KRAS) ; mitotic control homolog (DIS3)...
...CoMMpass (see "Initiating Mutations," page 5). In fact, only four genes appeared in both analyses: DIS3...
...Early growth response 1 (EGR1) Family with sequence similarity 46 member C (FAM46C) K-Ras (KRAS) Mitotic control homolog (DIS3)...
BioCentury | Aug 8, 2015
Financial News

Biotechs end bleak week with late rally

Biotech indices rallied late Friday after sinking earlier in the day, but still lost ground during the week. The BioCentury 100 shed 87.07 to 7,475.14 on Friday, while the NASDAQ Biotechnology Index (NBI) lost 27.29...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Ras homolog enriched in striatum (RHES; RASD2; TEM2)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest inhibiting RHES in the brain could help treat HD. In a transgenic mouse model of HD expressing mutant huntingtin (HTT) , systemic homozygous and heterozygous knockout of RHES...
Items per page:
1 - 10 of 39